华堂宁®

        华堂宁®

        固定剂量组合－dorzagliatin和口服药

        第二代GKA

        葡萄糖激酶调节剂

        果糖激酶抑制剂

        mGLUR5 NAM - CNS

        临床果糖检测

        A Novel Dual Pancreatic and Hepatic Acting Glucokinase Activator, HMS5552: Phase I Studies in Healthy Subjects and T2DM Patients

        Prediction of HMS5552 human pharmacokinetics using Allometric Scaling, IVIVE,Css-MRT and PBPK Modeling Methods （2016 中国药理学会定量药理学专业委员会年会）

        Clinical Proof of Concept (POC) of Glucokinase Activator HMS5552 Achieved in Chinese T2DM Patients: HbA1c Reduction of 1.22% with 100% Response Rate and Improved β-cell Function

        Clinical Proof of Concept (POC) of A Novel Dual-acting Glucokinase Activator (GKA) Achieved: HMS5552 improved glycemic control in T2DM Patients

        Pharmacodynamics Post-Hoc Analysis of Glucose Kinase Activator, Dorzagliatin (HMS5552) 12 Weeks Treatment in T2D Patients in China

        Type 2 Diabetes Patients Subtype Analysis: Unbiased Machine Learning for Future Personalized T2D Care

        Dorzagliatin differentiates from early generation of glucokinase activators: an enzyme kinetics study.

        Fragile X syndrome as a rare disease in China - Therapeutic challenges and opportunities.

        Clinically Differentiated Glucokinase Activator HMS5552: Effective Control of 24-Hour Glucose and Improvement of β Cell Function in T2DM Patients

        葡萄糖激酶激活剂HMS5552治疗4周对中国2型糖尿病患者胰岛β细胞功能影响的研究（2015 CDS）

        葡萄糖激酶激活剂HMS5552对2型糖尿病大鼠肝组织中葡萄糖激酶的调节作用 （2015 CDS）

        Validating the Dual-Modes of Action of HMS5552 A Novel Pancreatic- and Hepatic- Targeting Glucokinase Activator

        基于健康人PKPD特征预测首次患者试验（FIP）PKPD特征：一个机理创新降糖新药的例子（2014 临床药理学年会）

        Novel Dual‐acting Glucokinase Activator (GKA) Dorzagliatin (HMS5552) Achieved Primary Efficacy Endpoint with Good Safety Profiles in T2DM Patients Results of 24 Week Treatment in a Phase III Monotherapy Trial (SEED Study)

        The Anti-diabetic Effect of Dorzagliatin in Chinese Patients with Type 2 Diabetes.

        Dorzagliatin as a Glucose Sensitizer Achieved Sustained Glycemic Control in Drug-Naïve T2D Patients in a 52-Week Phase 3 Monotherapy Trial (SEED Study)

        Dorzagliatin as a Glucose Sensitizer Achieved Sustained Glycemic Control in Combination with Metformin in Chinese T2DM Patients in a 52-Week Phase 3 Clinical Trial (DAWN Study)

        Glucokinase Activator Dorzagliatin (HMS5552) Regulates GLP1 Release in T2D Patients and is Synergistic with Sitagliptin and Empagliflozin in Optimizing Beta Cell Function.

        Dorzagliatin Effect in Diabetes Remission (DREAM Study)

        Glucokinase Activator Restore Glucose Sensitivity and Early Phase Insulin Secretion in T2DM Patients: A Post-hoc Analysis of the Phase III Trials of Dorzagliatin.

        Dorzagliatin, a dual-acting glucokinase activator, improves insulin secretion and glucose sensitivity in glucokinase-maturity-onset diabetes of the young (GK-MODY) and recent-onset type 2 diabetes.

        Type 2 Diabetes Patients Subclassification Analysis: Personalized T2D Care of Dorzagliatin

        Link between Hyperglycemia and Cognitive Deficits in T2DM Animal Model

        Dorzagliatin Improves Beta-Cell Function in Patients with Type 2 Diabetes

        Dorzagliatin, a Glucokinase Activator, Repairs Defective Islet Function in High-Fat Diet-Induced Diabetic Mice

        Dorzagliatin, a Glucokinase Activator, Restores Glucose-Sensing in Type 2 Diabetic Human Islets

        Accessing Glucose Fluctuation—The Role of FPG, PPG, and HbA1c

        2018 MAY / Lancet Diabetes Endocrinology: New hope for glucokinase activators in type 2 diabetes?

        2018 May / Lancet Diabetes Endocrinology: Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study

        2018 April / Clinical Pharmacokinetics: Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration–Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics

        2018 February / Diabetes, Obesity and Metabolism: Dorzagliatin (HMS5552), a novel dual-acting glucokinase activator, improves glycaemic control and pancreatic β-cell function in patients with type 2 diabetes: A 28-day treatment study using biomarker-guided patient selection

        2017 January / Journal of Diabetes Research: Effects of a Novel Glucokinase Activator, HMS5552, on Glucose Metabolism in a Rat Model of Type 2 Diabetes Mellitus

        2016 December / Clinical Pharmacokinetics: Translational Modeling and Simulation in Supporting Early-Phase Clinical Development of New Drug: A Learn–Research–Confirm Process

        2016 October / Intractable & Rare Diseases Research: Orphan drug development in China ‒ Turning challenges into opportunities

        2016 May / Drug Design, Development and Therapy: Safety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator HMS5552: results from a first-in-human single ascending dose study

        2016年第3期《皇冠体育》：21世纪2型糖尿病新药研发策略：明鉴病理因素，改善机体功能

        2016年第3期《皇冠体育》：葡萄糖激酶激活剂研究进展

        2015 / Intractable & Rare Diseases Research：Fragile X syndrome as a rare disease in China – Therapeutic challenges and opportunities

        2020 June / Meta-analysis of the epidemiology of microvascular complications in people with Type 2 diabetes in mainland China

        2021 August, Clinical and Translational Science: Effect of renal impairment on the pharmacokinetics and safety of dorzagliatin, a novel dual-acting glucokinase activator.

        2022 May, Nature Medicine: Dorzagliatin in drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial

        2022 May, Nature Medicine: Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial

        2022 May, Nature Medicine Comments: A new class of drug in the diabetes toolbox.

        2023 March, Nature Communications: A phase I open-label clinical trial to study drug-drug interactions of Dorzagliatin and Sitagliptin in patients with type 2 diabetes and obesity

        Time in Range Estimation in Patients with Type 2 Diabetes is Improved by Incorporating Fasting and Postprandial Glucose Levels

        Diabetes remission in drug-naïve patients with type 2 diabetes after dorzagliatin treatment: A prospective cohort study

        Dorzagliatin, a Dual-Acting Glucokinase Activator, Increases Insulin Secretion and Glucose Sensitivity in Glucokinase Maturity-Onset Diabetes of the Young and Recent-Onset Type 2 Diabetes

        2018年中期报告

        2018年年报

        2019年中期报告

        2019年环境、社会及管治报告

        2019年年报

        2020年中期报告

        2020年环境、社会及管治报告

        2020年年报

        2021年中期报告

        2021年年报

        2021年环境、社会及管治报告

        2022年中期报告

        2022年年报

        2022年环境、社会及管治报告

        自愿性公告-产品研发管线的业务最新发展

        证券变动月报表

        购回股份及发行股份之一般授权、重选董事、授出购股权及股东周年大会通告

        证券变动月报表

        有关股东周年大会通告、通函及代表委任表格的澄清公告

        2019年6月24日（星期一）举行的 股东周年大会适用的经修订代表委任表格

        更改香港股份过户登记分处地址

        2019年6月24日举行的股东周年大会的投票表决结果

        证券变动月报表

        董事会召开日期

        授出购股权

        证券变动月报表

        证券变动月报表

        2019中期业绩公告

        2019年中期业绩公布的公告之补充公告

        业务最新发展 完成HMS5552 与二甲双胍联合用药治疗III期 临床试验所有受试者入组

        股东周年大会通告

        代表委任表格

        证券变动月报表

        2018皇冠体育app下载年度报告

        美国开展首项DORZAGLIATIN与SGLT-2抑制剂 联合用药的研究

        证券变动月报表

        授出购股权

        截至2018年12月31日止年度的年度业绩公告

        变更公司秘书及授权代表

        证券变动月报表

        业务最新发展 完 成HMS5552的III期单药治疗试验的患者招募

        董事会召开日期

        董事会成员多元化政策

        证券变动月报表

        自愿性公告-于美国开展首项DORZAGLIATIN与DPP-4抑制剂联合用药的研究

        证券变动月报表

        授出购股权

        证券变动月报表

        授出购股权

        证券变动月报表

        授出购股权

        翌日披露报表

        部分行使超额配股权、稳定价格行动及稳定价格期间结束

        证券变动月报表

        授出购股权

        本公司股东提名候选董事的程序

        战略委员会职权范围

        公司章程

        发售价及配发结果公告

        董事名单与其角色和职能

        董事会审核委员会职权范围

        董事会提名委员会职权范围

        董事会薪酬委员会职权范围

        股东通讯政策

        证券变动月报表

        业务最新发展关于Dorzagliatin的III期单药治疗临床研究的潜在内幕消息公告

        授出购股权

        有关租赁协议的须予披露交易

        证券变动月报表

        补充公告 - 有关租赁协议的须予披露交易

        变更公司秘书及授权代表

        证券变动月报表

        证券变动月报表

        董事会召开日期

        证券变动月报表

        截至2019年12月31日止年度的年度业绩公告

        授出购股权

        证券变动月报表

        授出购股权

        授出购股权

        2019年环境、社会及管治报告

        2019年年报

        自愿公告 — 皇冠体育宣布Dorzagliatin与恩格列净（一种SGLT-2抑制剂）联合用药临床研究的成功结果

        证券变动月报表

        2020年6月25日（星期四）举行的股东周年大会适用的代表委任表格

        (I)建议重选退任董事；(II)建议授出回购股份及发行股份之一般授权；(III)建议续聘核数师；及(IV)股东周年大会通告

        股东周年大会通告

        证券变动月报表

        自愿性公告－有关近期业务的最新进展皇冠体育宣布ß细胞功能的附加数据

        业务最新发展- 关于完成Dorzagliatin的III期单药试验SEED (HMM0301)

        2020年6月25日举行的股东周年大会的投票表决结果

        变更审核委员会成员

        董事名单与其角色和职能

        业务最新发展 - 关于Dorzagliatin与二甲双胍联合用药III期临床研究(HMM0302)的潜在内幕消息

        证券变动月报表

        授出购股权

        证券变动月报表

        董事会召开日期

        截至2020年6月30日止六个月的中期业绩公告

        业务最新发展 - 关于与拜耳就在研首创糖尿病新药Dorzagliatin在中国达成商业合作协议和战略合作的潜在内幕消息

        授出购股权

        证券变动月报表

        证券变动月报表

        证券变动月报表

        自愿性公告－ 有关近期业务的最新进展皇冠体育宣布BETA细胞功能的进一步数据

        证券变动月报表

        业务最新发展关于完成多扎格列艾汀与二甲双胍联合用药的III期临床试验DAWN(HMM0302)的潜在内幕消息

        证券变动月报表

        授出购股权

        证券变动月报表

        证券变动月报表

        董事会召开日期

        截至2020年12月31日止年度的年度业绩公告

        授出购股权

        证券变动月报表

        6月29日（星期二）举行的股东周年大会适用的代表委任表格

        (I)建议重选退任董事；(II)建议授出回购股份及发行股份之一般授权；(III)建议续聘核数师；及(IV)股东周年大会通告

        股东周年大会通告

        自愿性公告—多扎格列艾汀(dorzagliatin)新药上市申请已经正式获中国国家药品监督管理局(NMPA)受理

        有关通函之澄清公告

        (经修订) 证券变动月报表

        授出购股权

        证券变动月报表

        证券变动月报表

        2021年6月29日举行的股东周年大会的投票表决结果

         证券变动月报表

        证券变动月报表

        董事会召开日期

        截至2021年6月30日止六个月的中期业绩公告

        授出购股权

        证券变动月报表

        授出购股权

        业务最新发展 关于多格列艾汀糖尿病缓解的重要研究结果 潜在内幕消息

        证券变动月报表

        证券变动月报表

        证券变动月报表

        证券变动月报表

        证券变动月报表

        董事会召开日期

        证券变动月报表

        截至2021年12月31日止年度的年度业绩公告

        变更非执行董事及薪酬委员会成员

        董事名单与其角色和职能

        授出购股权

        证券变动月报表

        建议采纳新组织章程大纲及细则

        股东周年大会通告

        (I)建议重选退任董事；(II)建议授出回购股份及发行股份之一般授权；(III)建议续聘核数师；(IV)建议采纳新组织章程大纲及细则；及(V)股东周年大会通告

        2022年6月23日（星期四）举行的股东周年大会适用的代表委任表格

        证券变动月报表

        证券变动月报表

        2022年6月23日举行的股东周年大会的投票表决结果

        第二份经修订及经重述的组织章程大纲及细则

        授出购股权

        证券变动月报表

        更改香港股份过户登记分处地址

        证券变动月报表

        董事会召开日期

        截至2022年6月30日止六个月的中期业绩公告

        证券变动月报表

        证券变动月报表

        业务最新发展 - 全球首创新药华堂宁获批上市潜在内幕消息

        证券变动月报表

        自愿性公告 - (1)收购目标公司100%股权及(2)订立项目合作开发框架协议

        独立非执行董事辞世

        授出购股权

        证券变动月报表

        委任独立非执行董事及审核委员会及薪酬委员会组成的变动

        证券变动月报表

        证券变动月报表

        自愿性公告 - 关于就华堂宁的商业合作协定已收取里程碑付款的业务最新发展

        自愿性公告 - 有关华堂宁商业化进程的媒体报导的澄清及未经审核的业务最新发展

        证券变动月报表

        董事会召开日期

        截至2022年12月31日止年度的年度业绩公告

        独立非执行董事辞任及董事委员会组成变更

        董事名单与其角色和职能

        授出购股权

        持续关连交易 - 销售及分销框架协议

        证券变动月报表

        股东周年大会通告

        (I) 建议重选退任董事；(II)建议授出回购股份及发行股份之一般授权；(III)建议续聘核数师；及(IV)股东周年大会通告

        2023年6月29日（星期四）举行的股东周年大会适用的代表委任表格

        证券变动月报表

        授出购股权

        补充公告 - 持续关连交易销售及分销框架协议

        证券变动月报表

        2023年6月29日举行的股东周年大会的投票表决结果

        证券变动月报表

        证券变动月报表

        董事会召开日期

        关于华堂宁商业合作的业务最新发展

        截至2023年6月30日止六个月的中期业绩公告

        证券变动月报表

        全球发售

        白色申请表格

        黄色申请表格

        绿色申请表格

        2020年度业绩发布演示文稿

        公司介绍

        2021年中期业绩发布演示文稿

        2021年度业绩发布演示文稿

        2022年中期业绩交流会材料

        全球糖尿病首创新药华堂宁®获批上市

        2022年度业绩交流会材料

        2023年中期业绩发布演示文稿

        Jefferies 4th Annual Asia Forum

        瑞信亚洲投资论坛

        摩根大通全球中国峰会

        瑞银全球医疗会议

         美国糖尿病协会第79届年会

        2019年中期业绩发布会电话会

        26th CLSA Investors' Forum ( 2019/09/09 - 2019/09/13 Hong Kong)

        2018 年度业绩发布会

        Harnessing China Biotech's Potential (Bloomberg Intelligence)

        Trout Annual 1x1 Management Access Event 2019

        亚太生技投资论坛 (Diamond BioFund)

        高盛亚太地区医疗行业峰会

        China Healthcare Summit (BioCentury and BayHelix)

        出具2018年中期报告(本次活动不举办电话会议)

        Dorzagliatin单药治疗III期试验24周临床数据发布

        朱大龙教授权威解读：在研全球首创新药葡萄糖激酶激活剂（GKA）最新研究

        38th Annual J.P.Morgan Healthcare Conference（January 13-16, 2020）

        2019 年度业绩发布会

        UBS Virtual Global Healthcare Conference（May 18-20th, 2020）

        专顾资本亚太机遇峰会

        BIO国际大会

        中信证券2020年资本市场论坛

        信达证券中期策略会

        国泰君安 2020年医药健康行业投资峰会

        皇冠体育（2552.HK）2020年中期业绩发布会

        2020 HKEX Biotech Summit 2020

        中信证券“新格局的机遇”主题策略会

        ICA亚洲洞见论坛

        Citi China Investor Conference 2020

        皇冠体育2020年度业绩线上发布会

        2021年中期业绩线上发布会

        皇冠体育2021年度业绩线上交流会

        2022中期业绩交流会

        2022年度业绩交流会

        2023 中期业绩交流会

        皇冠体育正式在香港联交所挂牌交易

        “创新与开拓”——皇冠体育武汉分公司正式投入运营

        皇冠体育公布Dorzagliatin中国知识产权申请进展及临床III期试验进度

        皇冠体育于美国开展首项Dorzagliatin与DPP-4抑制剂联合用药的研究

        皇冠体育聘请Ralph Anthony DeFronzo 博士作为全球高级科学顾问

        皇冠体育公布最新研发管线皇冠体育HMS5552单药治疗III期临床试验完成所有受试者入组

        皇冠体育于美国启动首项Dorzagliatin与SGLT-2抑制剂联合用药的研究

        皇冠体育公布最新研发管线

        皇冠体育公布2019年中期业绩

        皇冠体育HMS5552二甲双胍联合用药治疗III期临床试验完成所有受试者入组

        皇冠体育聘请阿斯利康中国糖尿病领域资深人士担任营销战略和市场部副总裁

        皇冠体育在 D 轮和 E 轮融资中募集资金 1.174 亿美元

        美银美林资深投资银行家加入皇冠体育担任首席财务官

        HMS5552改善2型糖尿病早期患者胰岛功能，降低胰岛素抵抗

        皇冠体育app下载Argus药物警戒平台成功上线

        上海自贸区创新企业皇冠体育荣获自贸区“制度创新样本企业”

        首例受试者进入III期研究--皇冠体育重磅产品HMS5552达到重要里程碑

        “领控血糖，稳亦有道”-- 皇冠体育召开全球首创糖尿病治疗新药HMS5552临床III期启动会

        皇冠体育HMS5552获CFDA批准成为药品上市许可持有人（MAH）制度试点品种

        2016皇冠体育代谢论坛

        皇冠体育宣布新型糖尿病治疗药物单药治疗II期临床试验全球首次满意结果

        皇冠体育第76届ADA年会报道

        皇冠体育成功完成5,000万美元C轮融资

        糖尿病治疗新靶点--葡萄糖激酶激活剂--皇冠体育 CEO 陈力博士第十九届 CDS 全国学术会议专题报告

        皇冠体育 CEO 陈力博士、药物生产和监管副总裁李永国博士、临床研究和开发副总裁张怡博士出席 DIA 中国第一届药物研究创新会议并发表精彩演讲

        皇冠体育启动糖尿病原创新药中国Ⅱ期临床研究

        皇冠体育通过4周的Ic期临床研究证实糖尿病治疗药物GKA具有显著的治疗效果

        皇冠体育出席第二届代谢性疾病转化医学研讨会

        HMS5552的两张壁报获准在2015 ADA科学年会上展出

        皇冠体育HMS5552获准在美国开展Id期临床研究

        皇冠体育成功举办中国首个糖尿病全球原创新药第四代葡萄糖激酶激活剂HMS5552Ⅱ期临床研究者会

        皇冠体育正式向美国FDA递交新机制糖尿病创新药的临床研究申请

        皇冠体育宣布第四代葡萄糖激酶激活剂Ib期临床试验结果，显示该产品具有对糖尿病患者 24小时血糖有效调控能力

        皇冠体育B轮融资2500万美元,启动II期临床试验

        皇冠体育CEO陈力博士出席药物信息协会（DIA）第六届中国年会并发表演讲——New IND Process for the First in Class Drug CTA Approval at Ch

        皇冠体育新型葡萄糖激酶激活剂项目临床Ia试验成功证明其显著的对葡萄糖控制激素释放的调节功效，正式启动其在糖尿病患者中的临床Ib研究

        皇冠体育--糖尿病个性化治疗研究的先行者 首届中国代谢性疾病转化医学论坛报道

        皇冠体育CEO陈力博士第十七届北京国际生物医药产业发展论坛并发表演讲——中国药监局批准原创糖尿病新药首次进人临床研究：开通

        皇冠体育抗糖尿病创新药进入临床I期研究

        华医药从罗氏集团公司引进治疗糖尿病创新药

        重磅！皇冠体育全球首创新药III期注册临床研究结果首次公开学术报告

        喜报：皇冠体育全球首创新药亮相2019CDS全体会议主报告

        皇冠体育双重机制葡萄糖激酶激活剂 Dorzagliatin 在未用药 2 型糖尿病患者中开展的单药治疗 III 期注册临床研究达到主要疗效终点

        皇冠体育将于11月12日发布Dorzagliatin单药治疗III期临床试验24周顶线数据（HMM0301）

        皇冠体育宣布HMM0110和HMM0111临床研究成功结果

        皇冠体育任命前美国FDA官员汤福兴博士为首席技术官

        祝贺皇冠体育高级科学顾问Franz Matschinsky教授获得2020年Rolf Luft奖

        皇冠体育公布2019年全年业绩

        皇冠体育宣布Dorzagliatin与恩格列净（一种SGLT-2抑制剂）联合用药临床研究的成功结果

        皇冠体育获纳入MSCI香港微型股指数

        皇冠体育将在2020年ADA科学年会上报告单药治疗临床试验24周结果的全面数据

        皇冠体育成功完成Dorzagliatin单药治疗III期临床试验SEED研究（HMM0301）

        皇冠体育宣布Dorzagliatin与二甲双胍联合用药III期注册临床研究24周核心研究取得正面结果

        皇冠体育在美国糖尿病协会（ADA）第80届科学年会公布Dorzagliatin能够改善β细胞功能

        皇冠体育公布2020年中期业绩

        拜耳与皇冠体育宣布在糖尿病领域建立战略合作

        十年亮剑，皇冠体育创新引领新征程

        皇冠体育宣布获得《皇冠体育app下载》

        皇冠体育在CDS 2020上公布多格列艾汀的进一步研究数据

        皇冠体育宣布与瑞博制药建立商业化生产合作

        皇冠体育成功完成III期注册临床研究公布多格列艾汀与二甲双胍联合用药临床试验DAWN研究(HMM0302)的52周结果

        庆祝！皇冠体育全球运营总部和研发中心正式投入使用

        皇冠体育公布2020年全年业绩

        皇冠体育糖尿病首创新药多格列艾汀NDA获NMPA受理！为全球首个葡萄糖激酶激活剂

        捷报频传！皇冠体育CEO陈力博士荣获浦东重点工程“优秀建设者”称号

        皇冠体育将在2021年美国糖尿病协会（ADA）科学年会公布临床研究进展

        皇冠体育将在2021年美国糖尿病协会(ADA)科学年会公布多项临床研究进展

        皇冠体育公布2021年中期业绩

        皇冠体育与国药控股签署供应链战略合作协议，加速商业化布局

        皇冠体育SEED研究者将在中国医药创新与投资大会上公布有关糖尿病缓解的重要研究结果

        研究者公布有关多格列艾汀糖尿病缓解的重要研究

        “国际代谢疾病高峰论坛”论证“健康中国2030”创新途径

        皇冠体育宣布与合全药业签订针对多格列艾汀的商业化生产合作协议

        皇冠体育公布2021年全年业绩

        祝贺！国际顶级医学期刊《皇冠体育》同时发表两篇关于皇冠体育全球首创糖尿病新药多格列艾汀的III期研究结果的同行评议论文

        皇冠体育将在2022年美国糖尿病协会（ADA）科学年会展示多项临床研究成果

        皇冠体育在2022ADA科学年会公布多格列艾汀能够明显改善2型糖尿病患者和GCK-MODY 患者的胰岛素早相分泌和葡萄糖敏感性

        皇冠体育宣布多项人事任命，加速商业化步伐

        皇冠体育公布2022年中期业绩

        【皇冠体育】皇冠体育全球首创新药葡萄糖激酶激活剂华堂宁®获批上市！ 有望拓展中国2型糖尿病治疗新格局

        【皇冠体育】皇冠体育app下载创新路，中国华堂宁|皇冠体育举办全球首创新药华堂宁®成果展示会

        【皇冠体育】正式发售！皇冠体育GKA首创新药华堂宁®实现首单处方销售

        【皇冠体育】皇冠体育全球首创新药华堂宁®首次登上进博会舞台

        【皇冠体育】皇冠体育任命李长红博士为首席科学官 进一步推动公司研发创新

        【皇冠体育】皇冠体育全球首创新药葡萄糖激酶激活剂华堂宁®获编入世卫组织ATC代码系统

        【皇冠体育app下载】皇冠体育荣获工信部“2022中国医药新锐创新力量奖”

        【皇冠体育】皇冠体育首家官方旗舰店正式揭牌

        【皇冠体育】喜报 | 皇冠体育药品开发部获评浦东新区巾帼文明岗

        【皇冠体育】皇冠体育公布2022年全年业绩

        【皇冠体育】皇冠体育宣布多项人事任命

        【皇冠体育】皇冠体育成功举办投资者开放日活动

        【皇冠体育】皇冠体育入选2023年度中国生物医药科技创新价值榜

        【皇冠体育】皇冠体育将在2023年美国糖尿病协会（ADA）科学年会展示多项研究成果

        【皇冠体育】皇冠体育在2023ADA科学年会公布多格列艾汀在认知功能障碍方面的研究潜力

        【皇冠体育】皇冠体育发表全新研究论文，聚焦全球首创新药 多格列艾汀，52周内展现糖尿病缓解能力

        【皇冠体育】皇冠体育公布2023年中期业绩

        皇冠体育：创新“VIC＋Q”研发模式 推动Dorzagliatin为核心用药组合（转载自财经网）

        良药为民 - 皇冠体育勇闯创新之路 《皇冠体育》

        糖尿病全球首创新药重磅亮相ADA，这家中国公司火了！| ADA 2019 (转载自医学界内分泌频道)

        中国全球首创糖尿病治疗新药dorzagliatin携两项研究亮相ADA，最全解读在此 | ADA2019 (转载自国际糖尿病)

        糖尿病药物国产“代表作”明年申报上市（转载自新民晚报 ）

        张江：聚焦创新药研发 做强生物医药产业 （转自浦东广播电视台）

        央视2套《皇冠体育app下载》 新区新坐标 浦东新区探路先锋之皇冠体育

        全球首创糖尿病新药加速上市节奏 ：Ⅱ期报告出炉Ⅲ期临床启动

        《皇冠体育》张江皇冠体育十年磨一剑 全球首创糖尿病新药上市冲刺

        《皇冠体育》上海自贸区选出制度创新样本企业，企业：产品开发节省1亿多

        《皇冠体育app下载》浦东·故事 | 创业者陈力：扎根张江为中国人研发创新药

        转《皇冠体育》新闻制高点｜张江“药谷”生态环境催动企业创新

        《皇冠体育》中国原创糖尿病药首例受试者进入 Ⅲ 期临床研究

        新药开发节省1亿元提速2年！糖尿病新药三期临床启动

        你真的以为中国没有自主创新糖尿病药？其实它已开启 Ⅲ 期研究！

        皇冠体育启动全球首个葡萄糖激酶激活剂单药3期临床试验 | 现场

        创新药高峰论坛：中国追赶早期试验 | 第一现场

        里程碑：皇冠体育成为首家来自中国药企的CDISC会员

        “中国梦”提出四周年

        【皇冠体育app下载】上市许可持有人制度试行助推创新药物研发

        陈力谈中国医药创新 助力全民健康

        CDS2016 朱大龙教授牵头并分享葡萄糖激酶激活剂计划中国2型糖尿病验证性临床研究

        《皇冠体育app下载》皇冠体育-陈力专访

        Hua Medicine-on call to fight diabetes in China

        苏州创投大会：皇冠体育app下载糖尿病首创新药临床之旅 | 第一现场

        《皇冠体育》全自贸区内，多一些政策补助 ——专访皇冠体育app下载总经理陈力

        皇冠体育《皇冠体育app下载》打造中国的首创新药

        中国正在加速开发她的首个重磅炸弹药物

        上海张江高科技园区有望成为全球“药谷”

        张江药谷:打造全球生物医药“硅谷”

        《皇冠体育app下载》访皇冠体育张怡博士：皇冠体育app下载全球，做中国人自己的创新药

        华医药CEO陈力博士：开创新的医药企业运营模式

        华医药向中国市场引进罗氏治疗糖尿病创新药

        China Healthcare Report 2020

        Hua teams up with Bayer for dorzagliatin as diabetes treatment in China

        Hua's diabetes therapy may be first to show clinical remission

        张江药谷:打造全球生物医药“硅谷”

        皇冠体育《皇冠体育app下载》打造中国的首创新药

        Hua Medicine-on call to fight diabetes in China

        《皇冠体育app下载》皇冠体育-陈力专访

        陈力谈中国医药创新 助力全民健康

        “中国梦”提出四周年

        《皇冠体育》中国原创糖尿病药首例受试者进入 Ⅲ 期临床研究

        央视2套《皇冠体育app下载》 新区新坐标 浦东新区探路先锋之皇冠体育

        全球首创糖尿病新药加速上市节奏 ：Ⅱ期报告出炉Ⅲ期临床启动

        新闻制高点｜张江“药谷”生态环境催动企业创新

        张江：聚焦创新药研发 做强生物医药产业 （转自浦东广播电视台）

         皇冠体育 ADA TV 系列短片（第一部分）

         皇冠体育 ADA TV 系列短片（第二部分）

         皇冠体育 ADA TV 系列短片（第三部分）

         皇冠体育 ADA TV 系列短片（第四部分）

        全球首创糖尿病新药临床研究新成果发布 可改善餐后血糖波动性 安全及耐受性良好

        更高水平开放

        AI医疗：新发现 新场景 加速度丨元空间大放送

        “张江研发”十年一剑 全球首创糖尿病新药获批上市

        “张江研发”十年磨一剑 全球首创糖尿病新药获批上市

        上市获批仅一周 全球首创糖尿病新药启动生产

        上海：全球首创糖尿病新药开始投产

        兑现十年承诺，上海研发全球首创糖尿病新药领证投产

        历经十年 全球首创糖尿病新药在上海张江诞生|财经夜行线

        

        

        

        

        

        

        

        

        

        

        

        

        谢颖 , MBA

        佘劲，博士

        汤福兴，博士

        张怡，博士、医学博士

        林洁诚，法律博士

        陈力，博士

        董清，药学理学士

        李长红，博士

        浙江九洲药业股份有限公司

        南京药石科技股份有限公司

        凯莱英医药集团

        科文斯医药研发（北京）有限公司上海分公司

        西斯比亚医药技术（天津）有限责任公司

        上海迪赛诺生物制药有限公司（上海迪赛诺）

        上海合全药业股份有限公司（上海合全药业）

        方达医药技术有限公司

        上海药明津石医药科技有限公司

        上海康德弘翼医学临床研究有限公司

        杭州泰格医药科技股份有限公司

        上海奥科达生物医药科技有限公司

        康泰伦特

        上药康德乐

        辉士尔医药技术（北京）有限公司

        Zuellig Pharma

        华润(集团)有限公司

        柯乾（上海）医药技术有限公司

        缔脉生物医药科技(上海)有限公司

        Envigo CRS Ltd

        国家上海新药安全评价研究中心

        John J. Baldwin 博士

        James S. MacDonald 博士

        Bennett M. Shapiro 博士

        Catherine D. Strader 博士

        Ralph A. DeFronzo，博士

        张骥，博士

        Paul Chew，博士

        朱大龙 教授

        杨文英 教授

        Ralph A. DeFronzo 博士

        Franz M. Matschinsky 教授

        李小英 教授

        HuaTangNing (华堂宁®)

        HuaTangNing (华堂宁®) No dose adjustment in

        Fixed dose combinations - dorzagliatin and OADs

        2nd Generation GKA

        Glucokinase regulator

        Fructose Kinase Inhibitor

        mGLUR5 NAM - CNS

        Clinical Fructose detection

        A Novel Dual Pancreatic and Hepatic Acting Glucokinase Activator, HMS5552: Phase I Studies in Healthy Subjects and T2DM Patients

        Prediction of HMS5552 human pharmacokinetics using Allometric Scaling, IVIVE,Css-MRT and PBPK Modeling Methods （2016 中国药理学会定量药理学专业委员会年会）

        Clinical Proof of Concept (POC) of Glucokinase Activator HMS5552 Achieved in Chinese T2DM Patients: HbA1c Reduction of 1.22% with 100% Response Rate and Improved β-cell Function

        Clinical Proof of Concept (POC) of A Novel Dual-acting Glucokinase Activator (GKA) Achieved: HMS5552 improved glycemic control in T2DM Patients

        Pharmacodynamics Post-Hoc Analysis of Glucose Kinase Activator, Dorzagliatin (HMS5552) 12 Weeks Treatment in T2D Patients in China

        Type 2 Diabetes Patients Subtype Analysis: Unbiased Machine Learning for Future Personalized T2D Care

        Dorzagliatin differentiates from early generation of glucokinase activators: an enzyme kinetics study.

        Fragile X syndrome as a rare disease in China - Therapeutic challenges and opportunities.

        Clinically Differentiated Glucokinase Activator HMS5552: Effective Control of 24-Hour Glucose and Improvement of β Cell Function in T2DM Patients

        葡萄糖激酶激活剂HMS5552治疗4周对中国2型糖尿病患者胰岛β细胞功能影响的研究（2015 CDS）

        葡萄糖激酶激活剂HMS5552对2型糖尿病大鼠肝组织中葡萄糖激酶的调节作用 （2015 CDS）

        Validating the Dual-Modes of Action of HMS5552 A Novel Pancreatic- and Hepatic- Targeting Glucokinase Activator

        基于健康人PKPD特征预测首次患者试验（FIP）PKPD特征：一个机理创新降糖新药的例子（2014 临床药理学年会）

        Novel Dual‐acting Glucokinase Activator (GKA) Dorzagliatin (HMS5552) Achieved Primary Efficacy Endpoint with Good Safety Profiles in T2DM Patients Results of 24 Week Treatment in a Phase III Monotherapy Trial (SEED Study)

        The Anti-diabetic Effect of Dorzagliatin in Chinese Patients with Type 2 Diabetes.

        Dorzagliatin as a Glucose Sensitizer Achieved Sustained Glycemic Control in Drug-Naïve T2D Patients in a 52-Week Phase 3 Monotherapy Trial (SEED Study)

        Dorzagliatin as a Glucose Sensitizer Achieved Sustained Glycemic Control in Combination with Metformin in Chinese T2DM Patients in a 52-Week Phase 3 Clinical Trial (DAWN Study)

        Glucokinase Activator Dorzagliatin (HMS5552) Regulates GLP1 Release in T2D Patients and is Synergistic with Sitagliptin and Empagliflozin in Optimizing Beta Cell Function.

        Dorzagliatin Effect in Diabetes Remission (DREAM Study)

        Glucokinase Activator Restore Glucose Sensitivity and Early Phase Insulin Secretion in T2DM Patients: A Post-hoc Analysis of the Phase III Trials of Dorzagliatin.

        Dorzagliatin, a dual-acting glucokinase activator, improves insulin secretion and glucose sensitivity in glucokinase-maturity-onset diabetes of the young (GK-MODY) and recent-onset type 2 diabetes.

        Type 2 Diabetes Patients Subclassification Analysis: Personalized T2D Care of Dorzagliatin

        Link between Hyperglycemia and Cognitive Deficits in T2DM Animal Model

        Dorzagliatin Improves Beta-Cell Function in Patients with Type 2 Diabetes

        Dorzagliatin, a Glucokinase Activator, Repairs Defective Islet Function in High-Fat Diet-Induced Diabetic Mice

        Dorzagliatin, a Glucokinase Activator, Restores Glucose-Sensing in Type 2 Diabetic Human Islets

        Accessing Glucose Fluctuation—The Role of FPG, PPG, and HbA1c

        2018 MAY / Lancet Diabetes Endocrinology: New hope for glucokinase activators in type 2 diabetes?

        2018 May / Lancet Diabetes Endocrinology: Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study

        2018 April / Clinical Pharmacokinetics: Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration–Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics

        2018 February / Diabetes, Obesity and Metabolism: Dorzagliatin (HMS5552), a novel dual-acting glucokinase activator, improves glycaemic control and pancreatic β-cell function in patients with type 2 diabetes: A 28-day treatment study using biomarker-guided patient selection

        2017 January / Journal of Diabetes Research: Effects of a Novel Glucokinase Activator, HMS5552, on Glucose Metabolism in a Rat Model of Type 2 Diabetes Mellitus

        2016 December / Clinical Pharmacokinetics: Translational Modeling and Simulation in Supporting Early-Phase Clinical Development of New Drug: A Learn–Research–Confirm Process

        2016 October / Intractable & Rare Diseases Research: Orphan drug development in China ‒ Turning challenges into opportunities

        2016 May / Drug Design, Development and Therapy: Safety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator HMS5552: results from a first-in-human single ascending dose study

        2016年第3期《皇冠体育》：21世纪2型糖尿病新药研发策略：明鉴病理因素，改善机体功能

        2016年第3期《皇冠体育》：葡萄糖激酶激活剂研究进展

        2015 / Intractable & Rare Diseases Research：Fragile X syndrome as a rare disease in China – Therapeutic challenges and opportunities

        2020 June / Meta-analysis of the epidemiology of microvascular complications in people with Type 2 diabetes in mainland China

        2021 August, Clinical and Translational Science: Effect of renal impairment on the pharmacokinetics and safety of dorzagliatin, a novel dual-acting glucokinase activator.

        2022 May, Nature Medicine: Dorzagliatin in drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial

        2022 May, Nature Medicine: Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial

        2022 May, Nature Medicine Comments: A new class of drug in the diabetes toolbox.

        2023 March, Nature Communications: A phase I open-label clinical trial to study drug-drug interactions of Dorzagliatin and Sitagliptin in patients with type 2 diabetes and obesity

        Time in Range Estimation in Patients with Type 2 Diabetes is Improved by Incorporating Fasting and Postprandial Glucose Levels

        Diabetes remission in drug-naïve patients with type 2 diabetes after dorzagliatin treatment: A prospective cohort study

        Dorzagliatin, a Dual-Acting Glucokinase Activator, Increases Insulin Secretion and Glucose Sensitivity in Glucokinase Maturity-Onset Diabetes of the Young and Recent-Onset Type 2 Diabetes

        2018 Interim Report

        2018 Annual Report

        2019 Interim Report

        Environment, Social and Governance Report 2019

         2019 Annual Report

        2020 Interim Report

        2020 Environment, Social and Governance Report

        2020 Annual Report

        2021 Interim Report

        2021 Annual Report

        2021 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

        2022 Interim Report

        2022 Annual Report

        2022 Environmental, Social and Governance Report

        Shareholders’ Communication Policy

        Terms of Reference of the Audit Committee

        Terms of Reference of the Nomination Committee

        Terms of Reference of the Remuneration Committee

        List of Directors and their Role and Function

        Announcement of Offer Price and Allotment Results

        Articles of Association

        Terms of Reference of the Strategy Committee

        Procedures for Shareholders to Propose a Person for Election as a Director of the Company

        Grant of Share Options

        Monthly Return

        Partial Exercise of The Over-Allotment Option,Stabilizing Actions and End of Stabilization Period

        Next Day Disclosure Return

        Grant of Share Options

        Monthl Return

        Grant of Share Options

        Monthly Return

        Grant of Share Options

        Monthly Return

        VOLUNTARY ANNOUNCEMENT FIRST COMBINATION STUDY OF DORZAGLIATIN WITH A DPP-4 INHIBITOR IN THE UNITED STATES

        Monthly Return

        Board Diversity Policy

        Date of Board Meeting

        Business Update Completion Of Patient Enrollment For Phase III Monotherapy Trial Of Dorzagliatin

        Monthly Return

        Change Of Company Secretary And Authorised Representative

        Annual Results Announcement For The Year Ended December 31, 2018

        Grant of Share Options

        Monthly Return

        Voluntary Announcement First Combination Study Of Drzag With A SGLT-2 Inhibitor In The United States

        Hua Medicine Annual Report

        Monthly Return

        Form of Proxy

        General Mandates to Buyback and Issue Shares, Re-election of Directors, Approval of Share Option Grant...

        Notice of Annual General Meeting

        Voluntary Announcement - Business & Pipeline Update

        Monthly Return

        Clarification announcement on notice of annual general meeting, circular and proxy form

        Revised form of proxy for the annual general meeting to be held on monday, june 24, 2019

        Change of address of hong kong branch share registrar and transfer office

        Poll Results of the Annual General Meeting Held on June 24, 2019

        Monthly Return

        Date of Board Meeting

        Monthly Return

        2019 Interim results announcement

        Supplemental announcement in relation to the interim results announcement 2019

        Business Update Completion Of Patient Enrollment For Phase III Combination Trial Of Dorzagliatin

        Grant of share options

        Monthly Return

        Monthly Return

        Monthly Return

        Business update on first phase III monotherapy trial of dorzagliatin

        Grant of share options

        Discloseable transaction in relation to tenancy agreement

        Monthly Return

        Supplemental announcement discloseable transaction in relation to tenancy agreement

        Change of company secretary and authorised representative

        Monthly Return

        Monthly Return

        Date of Board Meeting

        Monthly Return

        Annual Results Announcement For The Year Ended December 31, 2019

        Grant of share options

        Monthly Return

        Grant of share options

        Grant of share options

        2019 Environment, Social and Governance Report

        2019 Annual Report

        Voluntary Announcement – Update Regarding Recent Business Developments

        Monthly Return

        Form of Proxy for the Annual General Meeting to be Held on Thursday, June 25, 2020

        (I) Proposed Re-election of Retiring Directors; (II) Proposed Granting of General Mandates to Repurchase Shares and to Issue Shares; (III) Proposed Re-appointment of Auditor; and (IV) Notice of Annual General Meeting

        Notice of Annual General Meeting

        Monthly Return

        Voluntary Announcement – Update Regarding Recent Business Developments

        Business Update on Completion of Seed (Hmm0301)

        Poll Results of the Annual General Meeting Held on June 25, 2020

        Change of Audit Committee Member

        List of Directors and their Role and Function

        Business Update on Completion of HMM0302, Dorzagliatin's Phase III Metformin Combination Trial Announcement of Potential Inside Information

        Monthly Return

        Grant of Share Options

        Monthly Return

        Date of Board Meeting

        Interim Results Announcement for the Six Months Ended June 30, 2020

        Business Update on Commercialization Agreement and Strategic Partnership for Investigational First-In-Class Novel Diabetes Treatment Dorzagliatin With Bayer in China Announcement of Potential Inside Information

        Grant of Share Options

        Monthly Return

        Monthly Return

        Monthly Return

        Voluntary Announcement – Update Regarding Recent Business Developments Hua Medicine Announces Additional Data in Beta-Cell Function

        Monthly Return

        Business Update on Completion of Dawn (Hmm0302), Dorzagliatin’S Phase III Metformin Combination Trial Announcement of Potential Inside Information

        Monthly Return

        Grant of Share Options

        Monthly Return

        Monthly Return

        Date of Board Meeting

        Annual results announcement for the year ended december 31, 2020

        Grant of Share Options

        Monthly Return

        Form of Proxy for the Annual General Meeting to be Held On Tuesday, June 29

        (I) Proposed Re-election of Retiring Directors; (II) Proposed Granting of General Mandates to Repurchase Shares and to Issue Shares; (III) Proposed Re-appointment of Auditor; (IV) Notice of Annual General Meeting

        Notice of Annual General Meeting

        Voluntary Announcement—New Drug Application for Dorzagliatin Accepted in China by the National Medical Products Administration

        Clarification Announcement Regarding The Circular

        (Revised) Monthly Return

        Grant of Share Options

        Monthly Return

        Monthly Return

        Poll results of the annual general meeting held on june 29, 2021

        Monthly Return

        Monthly Return

        Date of Board Meeting

        Interim results announcement for the six months ended june 30, 2021

        Grant of Share Options

        Monthly Return

        Grant of Share Options

        Business Update on Diabetes Remission of Dorzagliatin Announcement of Potential Inside Information

        Monthly Return

        Monthly Return

        Monthly Return

        Monthly Return

        Monthly Return

        Date of Board Meeting

        Monthly Return

        Annual Results Announcement For The Year Ended December 31, 2021

        Change of non-executive director and member of the remuneration committee

        List of directors and their role and function

        Grant of Share Options

        Monthly Return

        PROPOSED ADOPTION OF NEW MEMORANDUM AND ARTICLES OF ASSOCIATION

        NOTICE OF ANNUAL GENERAL MEETING

        (I) PROPOSED RE-ELECTION OF RETIRING DIRECTORS; (II) PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE SHARES; (III) PROPOSED RE-APPOINTMENT OF AUDITOR; (IV) PROPOSED ADOPTION OF NEW MEMORANDUM AND ARTICLES OF ASSOCIATION; AND (V) NOTICE OF ANNUAL GENERAL MEETING

        FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON THURSDAY, JUNE 23, 2022

        Monthly Return

        Monthly Return

        POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 23, 2022

        SECOND AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION

        GRANT OF SHARE OPTIONS

         Monthly Return

        CHANGE OF ADDRESS OF HONG KONG BRANCH SHARE REGISTRAR AND TRANSFER OFFICE

        Monthly Return

        Date of Board Meeting

        INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2022

        Monthly Return

        Monthly Return

        Business Update - Approval of NDA of Huatangning, Innovative First-In-Class GKA Potential Inside Information

        Monthly Return

        Voluntary announcement - (1) acquisition of 100% equity interests in the target company and (2) entering into of the project cooperative development framework agreement

        Passing away of an independent non-executive director

        Grant of share options

        Monthly Return

        Appointment of independent non-executive director and change in composition of audit committee and remuneration committee

        Monthly Return

        Monthly Return

        Voluntary Announcement - Business Update on Receipt of Milestone Payments Under The Commercialization Agreement in Relation to Huatangning

        Voluntary Announcement - Clarification and Unaudited Business Update in Relation to Media Coverage Relating to Commercialization Progress of Huatangning

        Monthly Return

        Date of board meeting

        Annual results announcement for the year ended december 31, 2022

        Resignation of independent non-executive director and change in composition of the board committees

        List of directors and their roles and functions

        Grant of share options

        Continuing connected transaction - sales and distribution framework agreement

        Monthly Return

        NOTICE OF ANNUAL GENERAL MEETING

        (I) PROPOSED RE-ELECTION OF RETIRING DIRECTORS;(II) PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE SHARES;(III) PROPOSED RE-APPOINTMENT OF AUDITOR;AND (IV) NOTICE OF ANNUAL GENERAL MEETING

        FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON THURSDAY, JUNE 29, 2023

        Monthly Return

        GRANT OF SHARE OPTIONS

        SUPPLEMENTAL ANNOUNCEMENT - CONTINUING CONNECTED TRANSACTION SALES AND DISTRIBUTION FRAMEWORK AGREEMENT

        Monthly Return

        POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 29, 2023

        Monthly Return

        Monthly Return

        Date of Board Meeting

        BUSINESS UPDATE IN RELATION TO THE COMMERCIALIZATION OF HUATANGNING

        INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2023

        Monthly Return

        Global Offering

        White Application Form

        Yellow Application Form

        Green Application Form

        2020 Annual Results Presentation

        Company Presentation

        2021 Interim Results Presentation

        2021 Annual Results Presentation

        2022 Interim Results Presentation

        华堂宁® Approved in China for T2D

        2022 Annual Results Presentation

        2023 Interim Results Presentation

        Jefferies 4th Annual Asia Forum

        Publication of 2018 Interim Results (no call scheduled)

        China Healthcare Summit (BioCentury and BayHelix)

        Goldman Sachs Asia Pacific Healthcare Forum

        Asia Pacific Biotech Investment Forum (Diamond BioFund)

        Trout Annual 1x1 Management Access Event 2019

        Harnessing China Biotech's Potential (Bloomberg Intelligence)

        2018 Annual Results Announcement

        Credit Suisse Asian Investment Conference

        J.P. Morgan's Annual Global China Summit

        UBS Global Healthcare Conference

        American Diabetes Association 79th Scientific Sessions

        2019 Interim Results Conference Call

        26th CLSA Investors' Forum ( Hong Kong)

        Dorzagliatin Monotherapy Phase III 24-week Data Announcement

        Dr Dalong Zhu presents: Latest Development from Glucokinase activator research

        38th Annual J.P.Morgan Healthcare Conference（January 13-16, 2020）

        2019 Annual Results Announcement

        UBS Virtual Global Healthcare Conference

        ICA Asia Pacific Opportunities Summit

        BIO International Convention

        CITICS Capital Market Conference 2020

        Cinda Security Conference

        Guotai Junan Pharmaceutical and Health Industry Investment Summit 2020

        Hua Medicine (2552.HK) 2020 Interim Results Briefing

        2020 HKEX Biotech Summit 2020

        中信证券“新格局的机遇”主题策略会

        ICA Asia Insights Forum

        Citi China Investor Conference 2020

        2020 Annual Results Announcement

        2021 Interim Results Announcement

        Hua Medicine 2021 Annual Results Announcement

        2022 Interim Results Announcement Webinar Invitation

        2022 Annual Results Earnings Call

        2023 Interim Results Earnings Call

        Good News: Hua Medicine’s Global First-in-Class Drug Was Presented at 2019 Scientific Meeting of CDS

        Hua Medicine’s Pivotal Phase III Monotherapy Trial of Dorzagliatin, a Dual-Acting Glucokinase Modulator, Achieves Primary Efficacy Endpoint in Patients with Type 2 Diabetes

        Hua Medicine to Release Phase III 24-Weeks Topline Data of Dorzagliatin Monotherapy Trial (HMM0301) on November 12

        Hua Medicine completes patient enrollment for Phase III combination with metformin trial of dorzagliatin

        Hua Medicine Announces 2019 Interim Results

        Hua Medicine – Recap of ADA 79th Scientific Sessions

        Hua Medicine – Business & Pipeline Update

        Hua Medicine Initiates First Combination Study of Dorzagliatin with SGLT-2 in the United States

        Hua Medicine Announces 2018 Annual Results

        Hua Medicine completes patient enrollment for Phase III monotherapy trial of dorzagliatin

        Hua Medicine Appoints Dr. Ralph Anthony DeFronzo as Distinguished Scientific Consultant

        Hua Medicine Initiates First Combination Study of Dorzagliatin with a DPP-4 Inhibitor in the United States

        Hua Medicine Announces Update on China IP of Dorzagliatin and Progress of Phase III Trials.

        Hua Medicine Successfully Completes Initial Public Offering and Listing on the Hong Kong Stock Exchange

        Hua Medicine hires AstraZeneca China Diabetes Veteran as VP, Head of Commercial Strategy and Marketing

        Hua Medicine Raises $117.4 Million in Series D & Series E Financing

        Bank of America Merrill Lynch Investment Banking Veteran Joins Hua Medicine as CFO

        Hua Medicine Announces First-Ever Successful Phase 2 Monotherapy Trial for New Class of Diabetes Drug

        Hua Medicine Successfully Completes 12-week Phase 2 Trial of Novel GKA Diabetes Drug

        Hua Medicine Raises $50 Million Series C Financing in Oversubscribed Round

        Hua Medicine’s GKA Diabetes Drug Demonstrates High Efficacy in 4-week Phase 1c Trial

        Hua Medicine Files IND in US for Its Novel GKA-Based Diabetes Drug

        Hua Medicine Announces Positive Phase 1b Results in Diabetes With 4th-Generation Glucokinase Activator, Shows Robust 24-Hour Glucose Control

        Hua Medicine Raises $25 Million in Series B Financing to Start Phase 2 Trials

        Hua Medicine's Novel Glucokinase Activator Reports Positive Phase 1a Data Demonstrating Robust Glucose Regulatory Hormone Modulation & Commences Phase 1b Trials in Diabetes Patients

        Hua Medicine Licenses Novel Drug Candidate from Roche for Potential Treatment of Diabetes

        Hua Medicine Lands $50M Financing Commitment for China Biopharmaceutical Innovation, Development and Commercialization

        Hua Medicine T2D Drug Entered into Clinical Trial in China

        Hua Medicine Presents First Public Academic Report on Phase III Registration Trial Results of its Global First-in-Class Drug

        Hua Medicine Announces Positive Results of HMM0110 and HMM0111

        Hua Medicine appoints Dr. Fuxing Tang, a former U.S. FDA Officer, as Chief Technology Officer

        Congratulations to Franz Matschinsky, Winner of the Rolf Luft Award 2020

        Hua Medicine Announces 2019 Annual Results

        Hua Medicine Announces Positive Results of the Combination Study of Dorzagliatin with Empagliflozin (a SGLT-2 inhibitor)

        Hua Medicine Selected for Inclusion in the MSCI Hong Kong Micro Cap Index

        Hua Medicine To Present Comprehensive Data of its 24-week Monotherapy Trial Results at 2020 ADA Scientific Sessions

        Hua Medicine Successfully Completes SEED (HMM0301), Dorzagliatin’s Phase III Monotherapy Trial

        Hua Medicine Announces Positive 24-Week Topline Results of Phase III Metformin Combination Trial of Dorzagliatin

        Hua Medicine's Dorzagliatin Demonstrates Improvements in β-Cell Function in Data Presented at the American Diabetes Association's 80th Scientific Sessions

        Hua Medicine Announces 2020 Interim Results

        Bayer and Hua Medicine announce commercialization agreement

        Hua Medicine Announces the Drug Manufacturing Permit Granted for Dorzagliatin

        Hua Medicine's Dorzagliatin Announces Additional Data to be Presented at CDS 2020

        Hua Medicine Announces the Commercialization Cooperation with Raybow Pharmaceutical

        Hua Medicine Successfully Completes Its Registration Phase III Trials. Announces 52-Week Results for DAWN (HMM0302), Dorzagliatin's Phase III Combination with Metformin Trial

        Hua Medicine Announces 2020 Annual Results

        Hua Medicine Announces Acceptance of a New Drug Application for Dorzagliatin in China - First Glucokinase Activator (GKA) Globally

        Hua Medicine to present additional dorzagliatin data at ADA 2021

        Hua Medicine to present additional dorzagliatin trials data at ADA 2021

        Hua Medicine Announces 2021 Interim Results

        Hua and Sinopharm Announced Supply Chain Strategic Cooperation

        Hua Medicine's SEED Researchers to Present Key Research Results on Diabetes Remission at the China BioMed Innovation and Investment Conference

        Researchers Present Key Research Results on Diabetes Remission of Dorzagliatin

        Hua Medicine Announces Supply Agreement with WuXi STA for Commercial Manufacturing of Dorzagliatin

        Hua Medicine Announces 2021 Annual Results

        Hua Medicine Published Two Peer-Reviewed Papers in Nature Medicine, an International Top Medical Journal, on the Results of the Phase III Research of Dorzagliatin, a First-In-Class Investigational Diabetes Drug of Hua Medicine

        Hua Medicine to Present Additional Clinical Results at ADA 2022

        Hua Medicine Announces Dorzagliatin can Restore Glucose Sensitivity and Early Phase Insulin Secretion in T2DM and GCK-MODY Patients at ADA 2022

        Hua Medicine Announces Multiple Personnel Appointments to Accelerate the Pace of Commercialization

        Hua Medicine Announces 2022 Interim Results

        [News] Hua Medicine's Innovative First-In-Class Glucokinase Activator (GKA) HuaTangNing(华堂宁®) Is Approved! New Type 2 Diabetes Treatment Paradigm to Begin in China

        [News] Hua Medicine Appoints Dr. Changhong LI as Chief Scientific Officer to Further Promote the Company's R&D Innovation

        [News] WHO Lists Hua Medicine's Innovative First-in-Class Glucokinase Activator (GKA) HuaTangNing in its ATC Classification System

        [News] Grand Opening Ceremony of Hua Medicine's First Online Flagship Store

        [News] Hua Medicine Announces 2022 Annual Results

        [News] Hua Medicine Announces Multiple Personnel Appointments

        [News] Hua Medicine will present multiple research results at the 2023 American Diabetes Association (ADA) Annual Scientific Sessions

        [News] Hua Medicine Announces the Potential of Dorzagliatin in Cognitive Dysfunction at ADA 2023

        New publication shines spotlight on Hua Medicine's Dorzagliatin ability to achieve diabetes remission over 52-week period

        [News]Hua Medicine Announces 2023 Interim Results

        Hua’s Institutional Advantage

        Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study

        Braced for the Biotech Boom

        China’s Hua Medicine seeks funding for US$200m diabetes drug development plan

        New Business in Action | Ep.2 New Drugs: Harvest Time is Coming

        Using Partnerships, Hua Medicine Brings Novel Diabetes Drug to Phase III

        The Chinese Dream on its Fourth Anniversary

        Sea turtles come back to China's biomedical industry

        Hua Medicine closes $50M round, looks to new diabetes target

        Hua Medicine Raises $50 Million to Develop and Commercialize Drugs

        Hua Medicine: A China Startup Led by Industry Veterans

        Hua Medicine-on call to fight diabetes in China

        China Healthcare Report 2020

        Hua teams up with Bayer for dorzagliatin as diabetes treatment in China

        Hua's diabetes therapy may be first to show clinical remission

        张江药谷:打造全球生物医药“硅谷”

        皇冠体育《皇冠体育app下载》打造中国的首创新药

        Hua Medicine-on call to fight diabetes in China

        《皇冠体育app下载》皇冠体育-陈力专访

        陈力谈中国医药创新 助力全民健康

        “中国梦”提出四周年

        《皇冠体育》中国原创糖尿病药首例受试者进入 Ⅲ 期临床研究

        央视2套《皇冠体育app下载》 新区新坐标 浦东新区探路先锋之皇冠体育

        全球首创糖尿病新药加速上市节奏 ：Ⅱ期报告出炉Ⅲ期临床启动

        新闻制高点｜张江“药谷”生态环境催动企业创新

        张江：聚焦创新药研发 做强生物医药产业 （转自浦东广播电视台）

         皇冠体育 ADA TV 系列短片（第一部分）

         皇冠体育 ADA TV 系列短片（第二部分）

         皇冠体育 ADA TV 系列短片（第三部分）

         皇冠体育 ADA TV 系列短片（第四部分）

        全球首创糖尿病新药临床研究新成果发布 可改善餐后血糖波动性 安全及耐受性良好

        更高水平开放

        AI医疗：新发现 新场景 加速度丨元空间大放送

        “张江研发”十年一剑 全球首创糖尿病新药获批上市

        “张江研发”十年磨一剑 全球首创糖尿病新药获批上市

        上市获批仅一周 全球首创糖尿病新药启动生产

        上海：全球首创糖尿病新药开始投产

        兑现十年承诺，上海研发全球首创糖尿病新药领证投产

        历经十年 全球首创糖尿病新药在上海张江诞生|财经夜行线

        

        

        

        

        

        

        

        

        

        

        

        

        Ying Xie, MBA

        Jin She, Ph.D

        Fuxing Tang, Ph.D

        Yi Zhang, Ph.D, M.D.

        George Lin, J.D.

        Li Chen, Ph.D

        Qing Dong, Bachelor of Pharmacy

        Changhong Li, Ph.D

        Zhejiang Jiuzhou Pharmaceutical Co., Ltd.

        PharmaBlock Sciences (Nanjing), Inc.

        Asymchem Inc.

        Covance Pharmaceutical R&D (Beijing) Co., Ltd. Shanghai Branch

        CCBR Clinical Research (Tianjin) Co., Ltd.

        Shanghai Desano Pharmaceuticals Co., Ltd

        Shanghai SynTheAll Pharmaceuticals Co., Ltd.

        Frontage Laboratories Co., Ltd.

        Shanghai MedKey Med-Tech Development Co., Ltd.

        WuXi Clinical Development Services (Shanghai) Co., Ltd.

        Hangzhou TigerMed Consulting Co., Ltd.

        Aucta Pharmaceuticals, Inc.

        Catalent Singapore Holdings Pte.Ltd.

        SPH KDL HEALTH

        Fisher Clinical Technology (Beijing) Co., Ltd.

        Zuellig Pharma

        China Resources (Holdings) Co., Ltd.

        ClinsChain (Shanghai) Clinical Services Co., Ltd.

        dMed Biopharmaceutical Co., Ltd.

        Envigo CRS Ltd.

        National Shanghai Center for New Drug Safety Evaluation and Research

        John J. Baldwin, Ph.D.

        James S. MacDonald, Ph.D.

        Bennett M. Shapiro, M.D.

        Catherine D. Strader, Ph.D.

        Ralph A. DeFronzo, M.D.

        Ji Zhang, Ph.D.

        Paul Chew, M.D.

        Dalong Zhu, M.D.

        Wenying Yang, M.D.

        Ralph A. DeFronzo, M.D.

        Franz Matschinsky, M.D.

        Xiaoying Li, MD, Ph.D.

        2018年中期報告

        2018年年報

        2019年中期報告

        2019年環境、社會及管治報告

        2019年年報

        2020年中期報告

        2020年環境、社會及管治報告

        2020年年報

        2021年中期報告

        2021年年報

        2021年環境、社會及管治報告

        2022年中期報告

        2022年年報

         2022年環境、社會及管治報告

        自願性公告-產品研發管線的業務最新發展

        證券變動月報表

        購回股份及發行股份之一般授權、重選董事、授出購股權及股東週年大會通告

        證券變動月報表

        有關股東週年大會通告、通函及代表委任表格的澄清公告

        2019年6月24日（星期一）舉行的 股東週年大會適用的經修訂代表委任表格

        更改香港股份過戶登記分處地址

        2019年6月24日舉行的股東週年大會的投票表決結果

        證券變動月報表

        董事會召開日期

        授出購股權

        證券變動月報表

        證券變動月報表

        2019中期業績公告

        2019年中期業績公佈的公告之補充公告

        業務最新發展 完成HMS5552 與二甲雙胍聯合用藥治療III期 臨床試驗所有受試者入組

        股東週年大會通告

        代表委任表格

        證券變動月報表

        2018華領年度報告

        美國開展首項DORZAGLIATIN與SGLT-2抑制劑 聯合用藥的研究

        證券變動月報表

        授出購股權

        截至2018年12月31日止年度的年度業績公告

        變更公司秘書及授權代表

        證券變動月報表

        業務最新發展 完 成HMS5552的III期單藥治療試驗的患者招募

        董事會召開日期

        董事會成員多元化政策

        證券變動月報表

        自願性公告-於美國開展首項DORZAGLIATIN與DPP-4抑制劑聯合用藥的研究

        證券變動月報表

        授出購股權

        證券變動月報表

        授出購股權

        證券變動月報表

        授出購股權

        翌日披露報表

        部分行使超額配股權、穩定價格行動及穩定價格期間結束

        證券變動月報表

        授出購股權

        本公司股東提名候選董事的程序

        戰略委員會職權範圍

        公司章程

        發售價及配發結果公告

        董事名單與其角色和職能

        董事會審核委員會職權範圍

        董事會提名委員會職權範圍

        董事會薪酬委員會職權範圍

        股東通訊政策

        證券變動月報表

        業務最新發展關於Dorzagliatin的III期單藥治療臨床研究的潛在內幕消息公告

        授出購股權

        有關租賃協議的須予披露交易

        證券變動月報表

        補充公告 - 有關租賃協議的須予披露交易

        變更公司秘書及授權代表

        證券變動月報表

        證券變動月報表

        董事會召開日期

        證券變動月報表

        截至2019年12月31日止年度的年度業績公告

        授出購股權

        證券變動月報表

        授出購股權

        授出購股權

        2019年環境、社會及管治報告

        2019年年報

        自願公告 — 華領醫藥宣佈Dorzagliatin與恩格列淨（一種SGLT-2抑制劑）聯合用藥臨床研究的成功結果

        證券變動月報表

        2020年6月25日（星期四）舉行的股東週年大會適用的代表委任表格

        (I)建議重選退任董事；(II)建議授出回購股份及發行股份之一般授權；(III)建議續聘核數師；及(IV)股東週年大會通告

        股東週年大會通告

        證券變動月報表

        自願性公告－有關近期業務的最新進展華領醫藥宣佈ß細胞功能的附加資料

        業務最新發展- 關於完成Dorzagliatin的III期單藥試驗SEED (HMM0301)

        2020年6月25日舉行的股東週年大會的投票表決結果

        變更審核委員會成員

        董事名單與其角色和職能

        業務最新發展 - 關於Dorzagliatin與二甲雙胍聯合用藥III期臨床研究(HMM0302)的潛在內幕消息

        證券變動月報表

        授出購股權

        證券變動月報表

        董事會召開日期

        截至2020年6月30日止六個月的中期業績公告

        業務最新發展 - 關於與拜耳就在研首創糖尿病新藥Dorzagliatin在中國達成商業合作協定和戰略合作的潛在內幕消息

        授出購股權

        證券變動月報表

        證券變動月報表

        證券變動月報表

        自願性公告－ 有關近期業務的最新進展華領醫藥宣佈BETA細胞功能的進一步數據

        證券變動月報表

        業務最新發展關於完成多紮格列艾汀與二甲雙胍聯合用藥的III期臨床試驗DAWN(HMM0302)的潛在內幕消息

        證券變動月報表

        授出購股權

        證券變動月報表

         證券變動月報表

        董事會召開日期

        截至2020年12月31日止年度的年度業績公告

        授出購股權

        證券變動月報表

        6月29日（星期二）舉行的股東週年大會適用的代表委任表格

        (I)建議重選退任董事；(II)建議授出回購股份及發行股份之一般授權；(III)建議續聘核數師；及(IV)股東週年大會通告

        股東週年大會通告

        自願性公告 - 多紮格列艾汀(dorzagliatin)新藥上市申請已經正式獲中國國家藥品監督管理局(NMPA)受理

        有關通函之澄清公告

        (經修訂) 證券變動月報表

        授出購股權

        證券變動月報表

        證券變動月報表

        2021年6月29日舉行的股東週年大會的投票表決結果

        證券變動月報表

        證券變動月報表

        董事會召開日期

        截至2021年6月30日止六個月的中期業績公告

        授出購股權

         證券變動月報表

        授出購股權

        業務最新發展 關於多格列艾汀糖尿病緩解的重要研究結果 潛在內幕消息

        證券變動月報表

        證券變動月報表

        證券變動月報表

        證券變動月報表

        證券變動月報表

        董事會召開日期

        證券變動月報表

        截至2021年12月31日止年度的年度業績公告

        變更非執行董事及薪酬委員會成員

        董事名單與其角色和職能

        授出購股權

        證券變動月報表

        建議採納新組織章程大綱及細則

        股東週年大會通告

        (I)建議重選退任董事；(II)建議授出回購股份及發行股份之一般授權；(III)建議續聘核數師；(IV)建議採納新組織章程大綱及細則；及(V)股東週年大會通告

        2022年6月23日（星期四）舉行的股東週年大會適用的代表委任表格

        證券變動月報表

        證券變動月報表

        2022年6月23日舉行的股東週年大會的投票表決結果

        第二份經修訂及經重述的組織章程大綱及細則

        授出購股權

         證券變動月報表

        更改香港股份過戶登記分處地址

        證券變動月報表

        董事會召開日期

        截至2022年6月30日止六個月的中期業績公告

        證券變動月報表

        證券變動月報表

        業務最新發展 - 全球首創新藥華堂寧獲批上市潛在內幕消息

        證券變動月報表

        自願性公告 - (1)收購目標公司100%股權及(2)訂立項目合作開發框架協議

        獨立非執行董事辭世

        授出購股權

        證券變動月報表

        委任獨立非執行董事及審核委員會及薪酬委員會組成的變動

        證券變動月報表

        證券變動月報表

        自願性公告 - 關於就華堂寧的商業合作協定已收取里程碑付款的業務最新發展

        自願性公告 - 有關華堂寧商業化進程的媒體報導的澄清及未經審核的業務最新發展

        證券變動月報表

        董事會召開日期

        截至2022年12月31日止年度的年度業績公告

        獨立非執行董事辭任及董事委員會組成變更

        董事名單與其角色和職能

        授出購股權

        持續關連交易 - 銷售及分銷框架協議

        證券變動月報表

        股東週年大會通告

        (I) 建議重選退任董事；(II)建議授出回購股份及發行股份之一般授權；(III)建議續聘核數師；及(IV)股東週年大會通告

        2023年6月29日（星期四）舉行的股東週年大會適用的代表委任表格

        證券變動月報表

        授出購股權

        補充公告 - 持續關連交易銷售及分銷框架協議

        證券變動月報表

        2023年6月29日舉行的股東週年大會的投票表決結果

        證券變動月報表

        證券變動月報表

        董事會召開日期

        關於华堂宁商業合作的業務最新發展

        截至2023年6月30日止六個月的中期業績公告

        證券變動月報表

        全球發售

        白色申請表格

        黃色申請表格

        綠色申請表格

        2020年度業績發布演示文稿

        公司介紹

        2021年中期業績發布演示文稿

        2021年度業績發布演示文稿

        2022年中期業績交流會材料

        全球糖尿病首創新藥華堂寧®獲批上市

        2022年度業績交流會材料

        2023年中期業績發布演示文稿

        Jefferies 4th Annual Asia Forum

        瑞信亞洲投資論壇

        摩根大通全球中國峰會

        瑞銀全球醫療會議

        美國糖尿病協會第79届年會

        2019年中期業績發佈會電話會

        26th CLSA Investors' Forum ( 2019/09/09 - 2019/09/13 Hong Kong)

        2018年度業績發佈會

        Harnessing China Biotech's Potential (Bloomberg Intelligence)

        Trout Annual 1x1 Management Access Event 2019

        亞太生技投資論壇 (Diamond BioFund)

        高盛亞太地區醫療行業峰會

        China Healthcare Summit (BioCentury and BayHelix)

        出具2018年中期報告(本次活動不舉辦電話會議)

        Dorzagliatin单药治疗III期试验24周临床数据发布

        朱大龙教授权威解读：在研全球首创新药葡萄糖激酶激活剂（GKA）最新研究

        38th Annual J.P.Morgan Healthcare Conference（January 13-16, 2020）

        2019 年度業績發佈會

        UBS Virtual Global Healthcare Conference（May 18-20th, 2020）

        專顧資本亞太機遇峰會

        BIO國際大會

        中信證券2020年資本市場論壇

        信達證券中期策略會

        國泰君安 2020年醫藥健康行業投資峰會

        華領醫藥（2552.HK）2020 年中期業績發布會

        2020 HKEX Biotech Summit 2020

        中信證券“新格局的機遇”主題策略會

        ICA亞洲洞見論壇

        Citi China Investor Conference 2020

        華領醫藥2020年度業績線上發佈會

        2021年中期業績線上發布會

        華領醫藥2021年度業績線上交流會

        2022中期業績交流會

        2022年度業績交流會

        2023 中期業績交流會